Publications

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece

Sep 29, 2023

Published on: Frontiers in Public Health
Authors: George Gourzoulidis, Myrto Barmpouni, Vasiliki Kossyvaki, Jeffrey Vietri, Charalampos Tzanetakos,

Abstract: Objective: Higher valency pneumococcal conjugate vaccines (PCVs) are expected to improve protection against pneumococcal disease through coverage of additional serotypes. The aim of the present study was to evaluate the cost-effectiveness of 20-valent...

Read More

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants

Aug 15, 2023

Published on: Vaccines (Basel)
Authors: Sophie Warren, Myrto Barmpouni, Vasiliki Kossyvaki, George Gourzoulidis, Johnna Perdrizet,

Abstract: In June 2010, Greece introduced the 13-valent pneumococcal conjugate vaccine (PCV13) for pediatric vaccination and has since observed a large decrease in pneumococcal disease caused by these vaccine serotypes, yet the disease prevalence of non-vaccine...

Read More

Does a Standard Cost-Effectiveness Threshold Exist? The Case of Greece

Mar 31, 2023

Published on: Value in Health Regional Issues
Authors: Charalampos Tzanetakos, George Gourzoulidis,

Abstract: Objectives: This study aimed to systematically review the use of cost-effectiveness (CE) threshold for evaluating pharmacological interventions in Greece. Methods: A systematic search of PubMed and ScienceDirect was conducted between January 2009 and June...

Read More

Archive per Year